TSHA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TSHA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Taysha Gene Therapies has the GF Value Rank of 0.
GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Taysha Gene Therapies's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul B Manning | director, 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Alison S Long | director | KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421 |
Kamran Alam | officer: Chief Financial Officer | 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118 |
Sean P. Nolan | director | C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005 |
Phillip B. Donenberg | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Stalfort John A Iii | director | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Session R.a. Ii | 10 percent owner | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Sukumar Nagendran | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015 |
Astellas Pharma Inc. | 10 percent owner | 2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411 |
Audentes Therapeutics, Inc. | 10 percent owner | 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108 |
Suyash Prasad | officer: CMO and Head of R&D | C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104 |
Laura Sepp-lorenzino | director | C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139 |
Kathleen Reape | director | C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235 |
From GuruFocus
By GuruFocus News • 02-14-2025
By Marketwired • 02-07-2025
By GuruFocus News • 02-25-2025
By Marketwired • 11-01-2024
By Marketwired • 10-22-2024
By GuruFocus News • 02-06-2025
By GuruFocus News • 02-27-2025
By GuruFocus News • 11-13-2024
By Marketwired • 09-26-2024
By Marketwired • 11-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.